As discussed before, CDCA treatment activated FXR and increased breast cancer cell proliferation and bone metastasis, while, in tamoxifen-resistant breast cancer cells, the activation of FXR by CDCA decreased cell proliferation through downregulating HER2 [125,126,128]. This evidence concerns the gene ERBB2 and breast carcinoma.